Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Grows By 7.3%

Health Catalyst, Inc. (NASDAQ:HCAT) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 2,340,000 shares, a growth of 7.3% from the August 31st total of 2,180,000 shares. Based on an average trading volume of 547,200 shares, the short-interest ratio is presently 4.3 days.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 5,208 shares of the business’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the transaction, the chief operating officer now owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,208 shares of Health Catalyst stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total transaction of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares in the company, valued at $954,572.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,361 shares of company stock worth $248,033. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its position in shares of Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after buying an additional 2,164 shares during the last quarter. Quarry LP boosted its position in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Health Catalyst by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after buying an additional 2,831 shares during the last quarter. Finally, ClariVest Asset Management LLC boosted its position in shares of Health Catalyst by 1.2% during the second quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after buying an additional 3,302 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Health Catalyst stock opened at $8.31 on Monday. The stock’s 50 day moving average is $7.41 and its 200 day moving average is $6.89. The firm has a market cap of $490.58 million, a P/E ratio of -4.49 and a beta of 1.31. Health Catalyst has a one year low of $5.42 and a one year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.21) earnings per share. Equities analysts anticipate that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HCAT shares. Evercore ISI decreased their price objective on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. JPMorgan Chase & Co. boosted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Piper Sandler cut their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, September 20th. Finally, Stephens cut their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.42.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.